KAZIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PNOC035 CLINICAL STUDY EVALUATING PAXALISIB FOR RECURRENT PEDIATRIC AT/RT BRAIN CANCER

Reuters · 1d ago

Please log in to view news